A box containing Canmab injectable medicine is displayed for a photograph at the Biocon Ltd. campus in Bengaluru. (Photographer: Dhiraj Singh/Bloomberg)

U.S. Drug Regulator Delays Decision On Biocon, Mylan’s Breast Cancer Biosimilar

The U.S. drug regulator has given Mylan Pharmaceuticals Pvt. Ltd. and Biocon Ltd. a three-month extension to get necessary approvals for selling a nearly identical copy of a breast cancer drug by S...